Advertisement
Advertisement

CAPR

CAPR logo

Capricor Therapeutics Inc

12.94
USD
-0.26
-1.97%
Dec 18, 13:51 UTC -5
Open

Capricor Therapeutics Inc Profile

About

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California.

Info & Links

CEO

Linda Marb¿n

Headquarters

10865 Road to the Cure, Suite 150
San Diego, CA 92121, UNITED STATES

Auditor

Rose, Snyder & Jacobs LLP

Share holders

126

Employees

102

Capricor Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

588.38M

Enterprise Value

520.00M

Enterprise Value/EBITDA(ttm)

-14.95

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

25.96

Price to Book(mrq)

8.82

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-146.86%

Profit Margin(ttm)

-259.52%

Return on Equity(ttm)

-112.95%

Return on Invested Capital(ttm)

-170.52%

Return on Assets(ttm)

-57.00%

Income Statement

Revenue(ttm)

23.23M

Revenue Per Share(ttm)

0.51

Gross Profit(ttm)

23.23M

EBITDA(ttm)3

-34.79M

Net Income Available to Common(ttm)

-34.11M

Diluted EPS(ttm)

-1.06

Share Statistics

Beta (5Y Monthly)

3.98

52-Week Change

308.20%

S&P 500 52-Week Change

27.88%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

45.47M

Dividend Yield

0.00%

Float4

40.01M

% Held by Insiders

12.00%

% Held by Institutions

21.68%

Balance Sheet

Total Cash(mrq)

85.03M

Total Cash Per Share(mrq)

1.87

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

4.19%

Quick Ratio(mrq)

4.19%

Book Value Per Share(mrq)

1.69

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.76

Free Cash Flow(ytd)

-26.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement